Contents

Search

diroximel fumarate (Vumerity)

Indications: - relapsing multiple sclerosis Dosage: - 462 mg PO BID Capsule: 231 mg delayed release Adverse effects: - flushing, abdominal pain, diarrhea, nausea Mechanism of action: - bioequivalent to dimethyl fumarate [3]

General

neurologic agent

Database Correlations

PUBCHEM cid=73330464

References

  1. RxNorm
  2. Brooks M FDA Clears More Tolerable Diroximel Fumarate (Vumerity) for MS. Medscape - Oct 30, 2019. https://www.medscape.com/viewarticle/920574
  3. DrugBank: Diroximel fumarate https://www.drugbank.ca/drugs/DB14783
  4. Highlights of Prescribing Information. Vumerity (diroximel fumarate) https://www.vumerityhcp.com/content/dam/commercial/vumerity/pat/en_us/pdf/vumerity-prescribing-information.pdf